Deucravacitinib (BMS-986165), an Oral, Allosteric Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement and Improves Quality of Life in Patients With Psoriasis. J of Skin 2020, 4 (6), s72. https://doi.org/10.25251/skin.4.supp.72.